Literature DB >> 21541441

Widespread deregulation of phosphorylation-based signaling pathways in multiple myeloma cells: opportunities for therapeutic intervention.

Gwenny Manel Fuhler1, Sander Henricus Diks, Maikel Petrus Peppelenbosch, William Garrow Kerr.   

Abstract

Multiple myeloma (MM) is a neoplasm of plasma cell origin that is largely confined to the bone marrow (BM). Chromosomal translocations and other genetic events are known to contribute to deregulation of signaling pathways that lead to transformation of plasma cells and progression to malignancy. However, the tumor stroma may also provide trophic support and enhance resistance to therapy. Phosphorylation of proteins on tyrosine, serine and threonine residues plays a pivotal role in cell growth and survival. Therefore, knowing the status of phosphorylation-based signaling pathways in cells may provide key insights into how cell growth and survival is promoted in tumor cells. To provide a more comprehensive molecular analysis of signaling disruptions in MM, we conducted a kinome profile comparison of normal plasma cells and MM plasma cells as well as their surrounding cells from normal BM and diseased BM. Integrated pathway analysis of the profiles obtained reveals deregulation of multiple signaling pathways in MM cells but also in surrounding bone marrow blood cells compared to their normal counterparts. The deregulated kinase activities identified herein, which include the mTOR (mammalian target of rapamycin)/p70S6K and ERK1/2 (extracellular signal-regulated kinases 1 and 2) pathways, are potential novel molecular targets in this lethal disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21541441      PMCID: PMC3146594          DOI: 10.2119/molmed.2011.00013

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  40 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Validated genomic approach to study differentially expressed genes in complex tissues.

Authors:  Elisa Wurmbach; Javier González-Maeso; Tony Yuen; Barbara J Ebersole; Jason W Mastaitis; Charles V Mobbs; Stuart C Sealfon
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

3.  Expression of nitric oxide synthase isoforms and nitrotyrosine immunoreactivity by B-cell non-Hodgkin's lymphomas and multiple myeloma.

Authors:  R V Mendes; A R Martins; G de Nucci; F Murad; F A Soares
Journal:  Histopathology       Date:  2001-08       Impact factor: 5.087

4.  A nitric oxide synthase inhibitor, N(G)-nitro-l-arginine-methyl-ester, exerts potent antiangiogenic effects on plasmacytoma in a newly established multiple myeloma severe combined immunodeficient mouse model.

Authors:  Shima Uneda; Hiroyuki Hata; Fumihiko Matsuno; Akitoshi Nagasaki; Naoko Harada; Yumi Mitsuya; Hiromitsu Matsuzaki; Hiroaki Mitsuya
Journal:  Br J Haematol       Date:  2003-02       Impact factor: 6.998

5.  Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.

Authors:  Pei Lin; Rebecca Owens; Guido Tricot; Carla S Wilson
Journal:  Am J Clin Pathol       Date:  2004-04       Impact factor: 2.493

6.  Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone.

Authors:  Thomas Strömberg; Anna Dimberg; Anna Hammarberg; Kristina Carlson; Anders Osterborg; Kenneth Nilsson; Helena Jernberg-Wiklund
Journal:  Blood       Date:  2003-12-24       Impact factor: 22.113

Review 7.  Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach.

Authors:  V Eleutherakis-Papaiakovou; M Karali; I Kokkonouzis; I Tiliakos; M A Dimopoulos
Journal:  Leuk Lymphoma       Date:  2003-06

8.  Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway.

Authors:  Jie Zhang; Yong Choi; Blanche Mavromatis; Alan Lichtenstein; Weiqun Li
Journal:  Oncogene       Date:  2003-09-18       Impact factor: 9.867

9.  Essential role of Src-family protein tyrosine kinases in NF-kappaB activation during B cell development.

Authors:  Kaoru Saijo; Christian Schmedt; I-Hsin Su; Hajime Karasuyama; Clifford A Lowell; Michael Reth; Takahiro Adachi; Alina Patke; Angela Santana; Alexander Tarakhovsky
Journal:  Nat Immunol       Date:  2003-02-03       Impact factor: 25.606

Review 10.  Survival and proliferation factors of normal and malignant plasma cells.

Authors:  Bernard Klein; Karin Tarte; Michel Jourdan; Karene Mathouk; Jerome Moreaux; Eric Jourdan; Eric Legouffe; John De Vos; Jean François Rossi
Journal:  Int J Hematol       Date:  2003-08       Impact factor: 2.490

View more
  9 in total

1.  Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.

Authors:  Miki Kiyota; Tsutomu Kobayashi; Shinichi Fuchida; Mio Yamamoto-Sugitani; Muneo Ohshiro; Yuji Shimura; Shinsuke Mizutani; Hisao Nagoshi; Nana Sasaki; Ryuko Nakayama; Yoshiaki Chinen; Natsumi Sakamoto; Hitoji Uchiyama; Yosuke Matsumoto; Shigeo Horiike; Chihiro Shimazaki; Junya Kuroda; Masafumi Taniwaki
Journal:  Int J Hematol       Date:  2012-03-17       Impact factor: 2.490

2.  Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells.

Authors:  Vidya Ramakrishnan; Donald E Mager
Journal:  J Pharmacol Exp Ther       Date:  2018-04-09       Impact factor: 4.030

3.  EphrinB2 controls vessel pruning through STAT1-JNK3 signalling.

Authors:  Ombretta Salvucci; Hidetaka Ohnuki; Dragan Maric; Xu Hou; Xuri Li; Sung Ok Yoon; Marta Segarra; Charles G Eberhart; Amparo Acker-Palmer; Giovanna Tosato
Journal:  Nat Commun       Date:  2015-03-26       Impact factor: 14.919

4.  Modulation of Human Peripheral Blood Mononuclear Cell Signaling by Medicinal Cannabinoids.

Authors:  Wesley K Utomo; Marjan de Vries; Henri Braat; Marco J Bruno; Kaushal Parikh; Mònica Comalada; Maikel P Peppelenbosch; Harry van Goor; Gwenny M Fuhler
Journal:  Front Mol Neurosci       Date:  2017-01-24       Impact factor: 5.639

5.  Detection and Characterization of Circulating Tumour Cells in Multiple Myeloma.

Authors:  Liangxuan Zhang; Sharon Beasley; Natalie L Prigozhina; Renee Higgins; Shoji Ikeda; Florence Y Lee; Dena Marrinucci; Shidong Jia
Journal:  J Circ Biomark       Date:  2016-01-01

6.  Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma.

Authors:  Congfen Li; Chikara Takahashi; Liangxuan Zhang; Mahrukh Huseni; Basha Stankovich; Haider Mashhedi; Joanna Lee; Dorothy French; Jeff Eastham Anderson; Doris Kim; Kathy Howell; Matthew J Brauer; Marcin Kowanetz; Yibing Yan; Eric Humke; Allen Ebens; Garret Hampton; Mark R Lackner; Priti Hegde; Shidong Jia
Journal:  J Transl Med       Date:  2013-03-23       Impact factor: 5.531

7.  PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex.

Authors:  Maria M Alves; Gwenny M Fuhler; Karla C S Queiroz; Jetse Scholma; Susan Goorden; Jasper Anink; C Arnold Spek; Marianne Hoogeveen-Westerveld; Marco J Bruno; Mark Nellist; Ype Elgersma; Eleonora Aronica; Maikel P Peppelenbosch
Journal:  Sci Rep       Date:  2015-09-28       Impact factor: 4.379

Review 8.  Kinome profiling.

Authors:  Maikel P Peppelenbosch
Journal:  Scientifica (Cairo)       Date:  2012-08-07

9.  Improved intra-array and interarray normalization of peptide microarray phosphorylation for phosphorylome and kinome profiling by rational selection of relevant spots.

Authors:  Jetse Scholma; Gwenny M Fuhler; Jos Joore; Marc Hulsman; Stefano Schivo; Alan F List; Marcel J T Reinders; Maikel P Peppelenbosch; Janine N Post
Journal:  Sci Rep       Date:  2016-05-26       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.